Recent Quotes

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Earnings

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-08-04
REV		(EXPECTED)2021-08-04

Q1 2021		Est.		Actual		Surprise
EPS		-0.230		-0.210		0.0200
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
ALNA	Allena Pharmaceuticals	1.28	-0.03	-2.29%		75.6M

Allena Pharmaceuticals Frequently Asked Questions

How do I buy Allena Pharmaceuticals (ALNA) stock?

You can purchase shares of Allena Pharmaceuticals (NASDAQ: ALNA) through any online brokerage.

View our list of the best stock brokerages.

Who are Allena Pharmaceuticals's (ALNA) competitors?

Other companies in Allena Pharmaceuticals’s space includes: PolarityTE (NASDAQ:PTE), Advaxis (NASDAQ:ADXS), Cleveland BioLabs (NASDAQ:CBLI), Celyad Oncology (NASDAQ:CYAD) and Monopar Therapeutics (NASDAQ:MNPR).

What is the target price for Allena Pharmaceuticals (ALNA) stock?

The latest price target for Allena Pharmaceuticals (NASDAQ: ALNA) was reported by HC Wainwright & Co. on June 1, 2020. The analyst firm set a price target for 10.00 expecting ALNA to rise to within 12 months (a possible 663.36% upside). 0 analyst firms have reported ratings in the last year.

Current Stock Price for Allena Pharmaceuticals (ALNA)?

The stock price for Allena Pharmaceuticals (NASDAQ: ALNA) is $1.31 last updated Tue Jun 22 2021 20:00:04 GMT+0000 (Coordinated Universal Time).

Does Allena Pharmaceuticals (ALNA) pay a dividend?

There are no upcoming dividends for Allena Pharmaceuticals.

When is Allena Pharmaceuticals (NASDAQ:ALNA) reporting earnings?

Allena Pharmaceuticals’s Q2 earnings are confirmed for after-market on August 4, 2021.

Is Allena Pharmaceuticals (ALNA) going to split?

There is no upcoming split for Allena Pharmaceuticals.

What sector and industry does Allena Pharmaceuticals (ALNA) operate in?

Allena Pharmaceuticals is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.